Roswell Park Comprehensive Cancer Center (founded 1898) is a cancer research and treatment center and a New York State public-benefit corporation located in Buffalo, New York and founded by Roswell Park. Candace S. Johnson is President & Chief Executive Officer of Roswell Park Comprehensive Cancer Center. In 2019, Roswell Park ranked #14 on U.S. News & World Report's list of the best cancer hospitals in the country, an increase from position #30 in 2018. Roswell Park was the first dedicated medical facility for cancer treatment and research in the United States, and is the only upstate New York facility to hold the National Cancer Institute designation of "comprehensive cancer center." Roswell Park Comprehensive Cancer Center, which conducts clinical research on cancer as well as developing new drugs, provides advanced treatment for all forms of adult and pediatric cancer and serves as a member of the National Comprehensive Cancer Network. The Roswell Park campus, spread out in 15 separate buildings of approximately two million square feet, occupies 28 acres (11 ha) on the 100-acre (40 ha) Buffalo Niagara Medical Campus (BNMC) in downtown Buffalo, and includes 1,500,000 square feet (140,000 m2) of space equally distributed between clinical programs and research/education functions. A separate hospital building, completed in 1998, houses a diagnostic and treatment center. The campus also includes a medical research complex as well as research and education focused space.
Advances in understanding the molecular landscape of gastroesophageal junction (GEJ) adenocarcinoma underscore the need for biomarker-driven treatment approaches. The Society of Surgical Oncology (SSO) Gastrointestinal (GI) Disease Site Working Group has developed practice guidelines for the biomarker-based management of nonmetastatic GEJ adenocarcinoma, with specific integration of microsatellite instability (MSI) status. Although multimodal therapy has improved outcomes, treatment strategies for GEJ adenocarcinoma remain largely stage-based rather than biomarker-directed. With emerging evidence supporting the prognostic and predictive roles of MSI-high (MSI-H), human epidermal growth factor receptor 2 (HER2), and other novel targets, there is an urgent need for clear guidance on how to incorporate biomarkers into the management of resectable disease. These guidelines provide evidence-based recommendations to support precision oncology in GEJ cancer care.
BACKGROUND:The peripheral nervous system can contribute to tumor development, progression, and metastasis; however, the clinical relevance of neuronal features within the tumor microenvironment in patients with gastric cancer (GC) remains to be fully elucidated. PATIENTS AND METHODS:Bulk transcriptomic and clinical data from publicly available databases were used to evaluate an xCell score that quantified the relative enrichment of neuron-associated gene expression programs in GC tumors. This allowed stratification into neuron score-high and neuron score-low groups within each cohort, with the upper two-thirds defined as high. Associations between neuronal enrichment and tumor biology were evaluated through analyses of neurotransmitter receptor expression, gene set enrichment, tumor microenvironment composition, genomic features, and patient survival. RESULTS:Neuron score-high GC exhibited characteristic enrichment of β-adrenergic, dopamine, and muscarinic acetylcholine receptor gene expression, consistent with enhanced neurochemical signaling potential. At the tumor cell level, the neuron score-high group was associated with activation of epithelial-mesenchymal transition (EMT) programs, whereas cell proliferation-related pathways were preferentially enriched in neuron score-low tumors. Neuron score-high tumors further displayed attenuated antitumor immune infiltration, increased stromal components, and elevated intratumor heterogeneity despite a lower mutation burden. Across both cohorts, neuron score-high tumors were associated with worse overall survival and remained independently associated with prognosis in multivariate analyses. CONCLUSIONS:Neuron score-high GC tumors were consistently associated with distinct patterns of neurotransmitter receptor gene expression, enhanced EMT programs with reduced cell proliferation, attenuated antitumor immune infiltration, increased intratumor heterogeneity, and worse prognosis. These observations identify the neuron score in bulk tumors as a potential indicator of GC biology.
Menin inhibitors (MENINi) show promise for relapsed or refractory (R/R) acute myeloid leukemia (AML) with KMT2A rearrangements (KMT2Ar) and NPM1 mutations (NPM1c). Outcomes after MENINi failure are poorly understood. To characterize the mutational landscape and subsequent outcomes, we conducted a multicenter retrospective study of adults from 4 U.S. centers with R/R AML after MENINi failure (relapse after response or primary refractory). The 84 patients (63% KMT2Ar, n=53; 23% NPM1c, n=19) who received MENINi were heavily pre-treated: 86% (n=72) had prior intensive chemotherapy (IC), 77% venetoclax (VEN, n=67), and 38% (n=32) allogeneic stem cell transplantation. After MENINi failure, 40% of patients (n=34) received supportive care. Of the 60% (n=50) that were treated, common regimens were hypomethylating agent (HMA)/VEN (26%, n=13), clinical trial (26%, n=13), and gilteritinib-based therapy (18%, n=9). The CR/CRi rate for non-trial therapies was 19% (n=7); ORR was 32% (n=12). All CR/CRi occurred with HMA/VEN (n=2, 15%), IC+VEN (n=4, 67%), or MENINi switching (bleximenib to revumenib, n=1, 50%). No FLT3-mutant patients responded to gilteritinib (0/6 gilteritinib-naïve). Median overall survival (mOS) from start of next therapy was 4.4 months; patients who achieved CR/CRi had mOS of 15.4 vs 3.4 months for non-responders (p=0.048). Outcomes after MENINi failure are poor, but responses occur with VEN-based regimens or MENINi switching. FLT3-ITD, WT1, and MEN1 mutations are associated with resistance.
Recent studies have applied machine learning (ML)-based limited sampling strategies (LSS) to predict drug exposure (AUC), achieving low prediction error and performance comparable to or better than multiple linear regression and population pharmacokinetics LSS. This study aimed to develop and validate a machine learning-based limited sampling strategy capable of predicting raltegravir (RAL) exposure. Four machine learning algorithms (XGBoost, Random Forest, GLMNet, and SVM) were trained using pharmacokinetic profiles generated via Monte Carlo simulation from a population pharmacokinetic (POPPK) model. Data were divided into training (75
Postoperative Gamma Knife Radiosurgery (GKRS) to resection cavities is standard for intracranial metastases, but the dynamics of these cavities after treatment and their relationship to local control remain incompletely defined. We retrospectively reviewed 98 patients with 98 resection cavities treated with single- or hypofractionated Gamma Knife radiosurgery (GKRS) between 2011 and 2025. Cavity volumes were segmented from serial contrast-enhanced MRI and compared with GKRS planning volumes. Longitudinal changes in log-transformed volumes were modeled using linear mixed-effects regression. Local recurrence–free survival (LRFS) and overall survival (OS) were estimated using Kaplan–Meier analysis, and associations with outcomes were tested using Cox proportional hazards models. Median imaging follow-up was 9.1 months (IQR 4.9–16.5), and cavities showed significant volume reduction over time (β = −0.031 ln[cc]/month, p < 0.001). Modeling indicated a nonlinear pattern, with greater reduction early and relative stabilization thereafter. At 12 and 24 months, actuarial local control was 74.5